Drug Profile
Research programme: viral RNA polymerase inhibitors - BioCryst
Alternative Names: BCX-5191; BCX4678; Hepatitis C virus RNA polymerase inhibitors - BioCrystLatest Information Update: 26 Feb 2013
Price :
$50
*
At a glance
- Originator BioCryst Pharmaceuticals; CNRS; Emory University
- Developer BioCryst Pharmaceuticals
- Class Nucleosides; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ebola virus infections; Hepatitis C; West Nile virus infections
Most Recent Events
- 31 Jan 2013 Discontinued - Preclinical for Hepatitis C in USA (PO)
- 31 Jan 2013 BioCryst terminates preclinical trial in Hepatitis C virus infection in USA
- 07 Dec 2012 BioCryst announces the company's strategic restructuring with focus on development of antiviral programmes, including BCX 5191 for HCV and a broad spectrum antiviral BCX 4430